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Variant interpretation is a central challenge in genomic
medicine. A recent study demonstrates the power of
Bayesian statistical approaches to improve interpretation
of variants in the context of specific genes and syndromes.
Such Bayesian approaches combine frequency (in the
form of observed genetic variation in cases and controls)
with biological annotations to determine a probability
of pathogenicity. These Bayesian approaches complement
other efforts to catalog human variation.Genome interpretation is the categorization or inference,Over the past 10 years, genome-wide diagnostic testing has
dramatically increased in both availability and utilization
across the clinical spectrum. Likewise, there has been a
corresponding shift in the nature of genetic inquiry from
locus-specific to genome-wide analysis. As the scale of
genetic data has expanded and genome-wide approaches
have become more common, data interpretation has
emerged as a central challenge. Genome-wide data inter-
pretation will probably continue to be a great challenge
for years to come, particularly as the data-generating
techniques expand from examining the coding sequence
(exome) towards analyzing the remaining 98% of human
DNA.
A research article in Genome Medicine by Ruklisa, Ware
and colleagues [1] now presents a key contribution to the
field of variant interpretation in the clinical domain of
heart phenotypes. Their approach applies the conceptual
framework of Bayesian statistics to address the interpret-
ative challenge. Other Bayesian frameworks have been
developed and used to analyze variants in genes associ-
ated with cancer predisposition syndromes [2] and copy* Correspondence: cashaw@bcm.edu
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article, unless otherwise stated.number variation [3]. The study by Ruklisa et al. [1] and
future work in this area hold great potential to transform
and improve variant interpretation, in terms of both speed
and cost of analysis and the accuracy of its conclusions.
Such methods should dramatically improve diagnostic
yields and could ultimately enhance the clinical utility of
genomic data. They represent an interdisciplinary mar-
riage of data depth and analytical expertise that are essen-
tial for the future of medicine.
What is genome interpretation?
starting from genome-wide genotype information, of in-
dividual variants or variant combinations as either causal
and potentially medically actionable or probably benign
and irrelevant with respect to medical indications. In the
context of reproductive genetics and genetic counseling,
inferences can also include determination of carrier sta-
tus for recessive disease and thus the reproductive risk.
In the context of cancer, genome interpretation can in-
clude choices of treatment methods [4].
A key aspect of the interpretive problem is the extent of
variation in genome-wide data, which can be thousands of
candidate single nucleotide variations (SNVs), copy num-
ber variations (CNVs) and small insertion-deletion events
(indels) observed in an individual patient. In principle, a
variety of sources of information can be used to substanti-
ate conclusions about the significance of variations, each
with its corresponding level of conclusiveness or ambigu-
ity. These types of evidence include patterns of segrega-
tion in families in which disease status co-occurs with
variant state(s); population-based association studies that
compare the frequency of a variant or variant sets between
unaffected individuals and cases; model organism studies
of specific variations (experimental genetic perturbations)
that recapitulate aspects of the phenotype; and experimen-
tal studies that characterize the specific molecular func-
tion and biochemical properties of variants in cellular
models of interest [5]. Variant interpretation can also beCentral. This is an Open Access article distributed under the terms of the
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that contain a wealth of information on transcription fac-
tor binding, epigenetic states, multi-species conservation,
protein structures and protein-protein interaction net-
works; these catalogs also include multi-species repositor-
ies of data for gene products and mutant phenotypes and
the vast collection of information contained in the bio-
medical literature.
Bayesian fusion of frequency and genomic
knowledge
The recent work brings together two conceptually distinct
types of information for variant analysis: frequency of vari-
ation in humans and annotation information about vari-
ants [1,3]. The integration of frequency and genomic data
is accomplished through the well developed paradigm
of Bayesian statistical reasoning. Bayesian analysis in-
volves two main components: a prior distribution on a
quantity of interest and a sampling distribution to update
this prior using observed information. In the recent paper
[1], the authors treat variant pathogenicity in a given pa-
tient as the unknown parameter. They place a prior dis-
tribution on this outcome using information on gene-level
variation frequency, and they use observed annotation
data corresponding to the particular variant to update the
probability of pathogenicity. This analysis determines
a synthetic score for variant pathogenicity, which proved
to be both sensitive and specific in the evaluations
performed.
The authors also customized their Bayesian models by
gene and disease context, focusing on three cardiac syn-
dromes [1]. In a new innovation, they also present separ-
ate families of Bayesian models for distinct classes of
SNVs and indels (radical, missense and in-frame indels).
Other authors had previously used a Bayesian approach
to analyze CNVs, using annotation data to specify the
prior and human frequency data to determine the likeli-
hood [3]. By making use of the well developed logical
foundations of Bayesian statistics - with its known bene-
fits and pitfalls - these Bayesian approaches for variant
analysis hold great promise to advance the field of inter-
pretation, making best use of decades of research in stat-
istical analysis.
Variant interpretation using a catalog look-up
approach
The important contribution of this recent paper [1] is its
potential to offer interpretative conclusions that are ra-
tionally substantiated in the absence of detailed specific
clinical knowledge about particular variants observed in in-
dividuals or small numbers of people. Genomic medicine
often relies on well established catalogs of specific variants
and variant databases to substantiate conclusions about
rare variants. There are a variety of such catalogs, includingthe Human Gene Mutation Database (HGMD), Online
Mendelian Inheritance in Man (OMIM), ClinVar [6] and
several phenotype-specific resources [7]. Large-scale efforts
[8] are underway to expand catalogs and considerable pub-
lic resources have been allocated in this direction.
The feasibility of cataloging or enumerating all pheno-
typically relevant human genetic variation is opposed by
underlying physical principles. Human variation is an
open physical system in which each human birth gener-
ates new variation. There are 3 billion bases of human
DNA, and thus a vast number of variations if we consider
all possible CNV and indel events. Expanding to variant
combinations, there are 4.5 × 1018 possible pairs of nu-
cleotide variants. The number of variations, combinations
of variations and the potentially pathogenic variants rivals
the size of the entire human family. Moreover, principles
of population genetics show that in the context of an
expanding population, as in the case of the recent super-
exponential growth of human populations, most variation
has emerged recently and is not widely shared within a
population [9]. In this context, differentiating phenotypic-
ally meaningful variation from variation that is merely rare
is a challenge. Variant cataloging relies on the idea that
by aggregating data on disease-causing variations and pu-
tative causal variations, we will eventually develop a
comprehensive and definitive resource. Large-scale and
expensive approaches that collate these data in adult dis-
ease, such as the Cancer Genome Atlas [10], have revealed
that much genetic variation underlying disease states is
sparse and extremely personal. Although documenting
and cataloging observed variation together with evidence
of pathogenicity is useful, other approaches will almost
certainly be necessary.
The benefits and dangers of Bayesian approaches
In the face of this complexity, the Bayesian approach of-
fers a variety of benefits. First, it combines different kinds
of information, making better use of current knowledge.
Second, it can propose an interpretation based on diverse
available information when there is only singleton and
sparse variation. Third, its conclusions are provided not as
binary decisions, but as a continuous scale that more
transparently reflects our state of uncertainty rather than
a false sense of certainty.
Despite the positives, there are limitations to a Bayesian
approach. First and foremost, there are many parameters
and distributional details that must be specified in a Bayesian
analysis, and these modeling choices can have an immense
impact. In the recent paper [1], many choices are made in
terms of default variant frequency and coefficient parame-
ters, and future work can provide guidance on the stability
of the conclusions made from the analyses. Perhaps more
importantly, any Bayesian analysis is by definition influ-
enced by prior knowledge and consequently can suffer from
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derstanding in some areas but suffers unknown gaps in
others. The Bayesian approach can reinforce such biases.
The complexity of genome-wide variation is daunting,
and in the face of this complexity computational tools
are an absolute necessity to improve diagnostics. This
work by Ruklisa et al. [1] makes an important contribu-
tion, extending Bayesian integration of frequency and
annotation knowledge to exome analysis in specific syn-
dromes. Further work in developing frameworks for
interpreting variants will pave the way to improving the
understanding and utility of genomic medicine.
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